Mental Health, Mental Illness & Addiction: CMA Submission to the Standing Committee on Social Affairs, Science and Technology

https://policybase.cma.ca/link/policy950

POLICY TYPE: Parliamentary submission
LAST REVIEWED: 2012-03-03
DATE: 2005-04-20
TOPICS: Population health, health equity, public health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Cannabis for Medical Purposes

CMA POLICY

PHYSICIANS

The Canadian Medical Association (CMA) recognizes the urgency of requirements for improved evidence-based guidelines for medical prescribing of cannabis for medical relief of symptoms of conditions for which conventional therapies have not been effective or for which conventional therapies are contraindicated or carry unacceptable risks.

The CMA further recognizes the need for a system of improved education and for a system of cooperation among health practitioners and practitioners of other health professions in this area.

Following are recommendations for the use of cannabis for medical purposes. These recommendations are based on current scientific evidence and on the experience of health practitioners.

The CMA encourages its members to

1. Support the advancement of scientific knowledge about the medical use of cannabis. For this purpose, the CMA will support appropriate public health measures, including research into the safety and efficacy, toxicology, clinical use, and the potential adverse effects of long-term use of cannabis.

2. Support consumers' and patients' access to safe, effective, and affordable products containing cannabis that are appropriate for their needs.

3. Support the development of guidelines for the use of cannabis for medical purposes in their practice setting at the College of Physicians and Surgeons of British Columbia, for the College of Physicians and Surgeons of Ontario, for the College of Physicians and Surgeons of Manitoba, and for the College of Physicians and Surgeons of Saskatchewan.

The CMA encourages health practitioners to keep informed about developments in the field of research and to consult current evidence-based guidelines when prescribing cannabis for medical purposes.

The CMA encourages health practitioners to keep informed about developments in the field of research and to consult current evidence-based guidelines when prescribing cannabis for medical purposes.

The CMA encourages health practitioners to keep informed about developments in the field of research and to consult current evidence-based guidelines when prescribing cannabis for medical purposes.
POLICY TYPE: Policy document
LAST REVIEWED: 2019-03-03
DATE: 2011-05-28
REPLACES: Medication use and seniors
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA Presentation to the Senate Standing Committee on Social Affairs, Science and Technology – Prescription Drugs: Clinical Trials and Approval
https://policybase.cma.ca/link/policy10437

POLICY TYPE
Parliamentary submission

DATE
2012-05-09

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA's Submission to the Senate Committee on Social Affairs, Science and Technology

Prescription Drugs: Clinical Trials and Approval

Prepared by:
Dr. Mark Roberts
Chair - Pain and Policy

May 8, 2012

Check against delivery

A formal examination of the clinical and regulatory procedures for medications is outside the scope of this submission.

A comprehensive overview of the control and oversight of prescription drugs is outside the scope of this submission.

A comprehensive overview of the control and oversight of prescription drugs is outside the scope of this submission.
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2012-12-08

TOPICS
Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA Response: Health Canada's Medical Marijuana Regulatory Proposal
https://policybase.cma.ca/link/policy10702

POLICY TYPE  Parliamentary submission
DATE  2013-02-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Position statement on prescription drug shortages in Canada
https://policybase.cma.ca/link/policy10756

POLICY TYPE
Policy document

LAST REVIEWED
2017-03-04

DATE
2013-05-25

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada: Canadian Medical Association Submission to the House of Commons Standing Committee on Health

https://policybase.cma.ca/link/policy11035

POLICY TYPE
Parliamentary submission

DATE
2013-11-27

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Review of Controlled Drugs and Substances Act: Canadian Medical Association submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations

https://policybase.cma.ca/link/policy11114

POLICY TYPE
Response to consultation

DATE
2014-03-17

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety
https://policybase.cma.ca/link/policy11125

POLICY TYPE: Parliamentary submission
DATE: 2014-03-26
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
The Health risks and harms associated with the use of marijuana

https://policybase.cma.ca/link/policy11138

POLICY TYPE
Parliamentary submission

DATE
2014-05-27

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Proposed amendments to the marihuana for medical purposes regulations
https://policybase.cma.ca/link/policy11293

POLICY TYPE: Response to consultation
DATE: 2014-07-11
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents
Tamper Resistance under the Controlled Drugs and Substances Act
https://policybase.cma.ca/link/policy11295

POLICY TYPE
Response to consultation

DATE
2014-08-26

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)
https://policybase.cma.ca/link/policy11297

POLICY TYPE  Parliamentary submission
DATE  2014-10-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Authorizing Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy11514

POLICY TYPE  Policy document
LAST REVIEWED  2020-02-29
DATE  2015-02-28
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-2 An Act to amend the Controlled Drugs and Substances Act (Respect for Communities Act)

https://policybase.cma.ca/link/policy11519

POLICY TYPE  Parliamentary submission
DATE  2015-05-14
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents